Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) shares, rose in value on Friday, 05/13/22, with the stock price up by 1.55% to the previous day’s close as strong demand from buyers drove the stock to $35.34.
Actively observing the price movement in the last trading, the stock closed the session at $34.80, falling within a range of $34.19 and $35.43. The value of beta (5-year monthly) was 0.71 whereas the PE ratio was 28.41 over 12-month period. Referring to stock’s 52-week performance, its high was $44.46, and the low was $17.56. On the whole, AMPH has fluctuated by -16.43% over the past month.
With the market capitalization of Amphastar Pharmaceuticals Inc. currently standing at about $1.80 billion, investors are eagerly awaiting this quarter’s results, scheduled for Mar 14, 2022 – Mar 18, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.37, which is expected to increase to $0.31 for fiscal year $1.32 and then to about $1.49 by fiscal year 2022. Data indicates that the EPS growth is expected to be 106.20% in 2022, while the next year’s EPS growth is forecast to be 12.90%.
Analysts have estimated the company’s revenue for the quarter at $112.08 million, with a low estimate of $109 million and a high estimate of $116.39 million. According to the average forecast, sales growth in current quarter could jump up 16.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $428.96 million, representing an increase of 22.60% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that AMPH’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 1.14, with the price of AMPH currently trading nearly -1.79% and -0.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.71, while the 7-day volatility ratio is showing 5.82% which for the 30-day chart, stands at 5.06%. Furthermore, Amphastar Pharmaceuticals Inc. (AMPH)’s beta value is 0.64, and its average true range (ATR) is 1.83. The company’s stock has been forecasted to trade at an average price of $38.25 over the course of the next 52 weeks, with a low of $32.00 and a high of $45.00. Based on these price targets, the low is 9.45% off current price, whereas the price has to move -27.33% to reach the yearly target high. Additionally, analysts’ median price of $38.00 is likely to be welcomed by investors because it represents a decrease of -7.53% from the current levels.
A comparison of Amphastar Pharmaceuticals Inc. (AMPH) with its peers suggests the former has fared considerably weaker in the market. AMPH showed an intraday change of 1.55% in last session, and over the past year, it grew by 76.97%%. In comparison, SCYNEXIS Inc. (SCYX) has moved higher at 10.70% on the day and was down -70.89% over the past 12 months. On the other hand, the price of Agile Therapeutics Inc. (AGRX) has fallen -1.21% on the day. The stock, however, is off -97.47% from where it was a year ago. The PE ratio stands at 28.41 for Amphastar Pharmaceuticals Inc. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.
Data on historical trading for Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) indicates that the trading volumes over the past 3 months, they’ve averaged 486.95K. According to company’s latest data on outstanding shares, there are 47.83 million shares outstanding.
Nearly 5.60% of Amphastar Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 61.60% of the company’s shares. The stock has risen by 51.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AMPH stock heading into the next quarter.